Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.49 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 4/20 | 0.44 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | BPTF | Q12830 | 1/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30929457 | 0.99 | BRD4 (0.50) | BRD4BRD9F2F7F3 | |
| SCHEMBL30929399 | 0.89 | F2 (0.47) | BRD4BRD9F2F7F3 | |
| SCHEMBL30929434 | 0.87 | BRD4 (0.46) | BRD4BRD9F2F7F3 | |
| SCHEMBL30929475 | 0.86 | F2 (0.46) | BRD4BRD9F2F7F3 | |
| SCHEMBL30929452 | 0.85 | F2 (0.45) | BRD4BRD9F2F7F3 | |
| SCHEMBL30929474 | 0.85 | PREP (0.43) | BRD4BRD9F2F7F3 | |
| SCHEMBL30929451 | 0.84 | F2 (0.44) | BRD4BRD9F2F7F3 | |
| SCHEMBL30929448 | 0.82 | F2 (0.42) | BRD4BRD9F2F7F3 | |
| SCHEMBL30929440 | 0.82 | F2 (0.43) | F2F7F3PREP | |
| SCHEMBL30929431 | 0.81 | BRD4 (0.48) | BRD4BRD9F2F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626891-A1 | FUSED PYRIMIDINES AS MASP-2 INHIBITORS | Omeros Corporation (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20240228499-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024118840-A1 | FUSED PYRIMIDINES AS MASP-2 INHIBITORS | OMEROS CORPORATION (US) | 2024-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228499-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, SPINT2, SERPINB1 | BRD4 2146/4885BRD9 2420/4885F2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.